Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Retatrutide: The Complete Triple Agonist Protocol Guide (2026)
Category: Protocols Type: Protocol Read Time: 20 minutes Author: Peptides.NYC Editorial Last Updated: 2026-04-10 URL: https://peptides.nyc/learn/retatrutide-protocol
Overview
The next-generation GIP/GLP-1/Glucagon triple agonist showing 24% weight loss in trials. Understanding triple receptor activation, clinical trial dosing from 1mg to 12mg, comparing to tirzepatide and semaglutide, Phase 3 trial updates, and what to expect from this breakthrough compound.
What is Retatrutide?
Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly. It activates three key metabolic receptors:
- GLP-1 (Glucagon-Like Peptide-1)
- GIP (Glucose-dependent Insulinotropic Polypeptide)
- Glucagon
This triple mechanism represents the next evolution beyond dual agonists like tirzepatide.
Development Status (2026):
- Phase 3 clinical trials ongoing
- FDA approval expected 2025-2026
- Currently available through clinical trials and research
How Retatrutide Works
Triple Mechanism Explained:
GLP-1 Activation:
- Reduces appetite and food intake
- Slows gastric emptying
- Improves glucose-dependent insulin secretion
- Decreases glucagon secretion
GIP Activation:
- Enhances GLP-1 effects synergistically
- Improves fat metabolism
- Additional insulin secretion support
- Better tolerability than GLP-1 alone
Glucagon Activation (The Game-Changer):
- Increases energy expenditure
- Promotes fat oxidation
- Enhances thermogenesis
- Helps prevent muscle loss during weight loss
Why Triple is Revolutionary:
The glucagon component addresses a key limitation of GLP-1 drugs: they primarily reduce food intake but don't significantly increase energy expenditure. Retatrutide does both.
Clinical Trial Results
Phase 2 Trial (48 weeks):
Weight Loss by Dose:
| Dose | Average Weight Loss | 20%+ Loss |
|---|---|---|
| 1mg | 8.7% | N/A |
| 4mg | 17.1% | ~40% |
| 8mg | 22.8% | ~60% |
| 12mg | 24.2% | ~67% |
| Placebo | 2.1% | N/A |
Key Findings:
- 24% average weight loss at highest dose (12mg)
- Some participants lost up to 30%+ body weight
- Superior to semaglutide (15-17%) and tirzepatide (20-22%)
- Weight loss continued through week 48 (curve not plateaued)
Metabolic Improvements:
- Significant A1C reduction in diabetic patients
- Improved blood pressure
- Better lipid profiles
- Reduced liver fat (up to 80% reduction in some studies)
Dosing Protocol (From Clinical Trials)
Phase 2 Titration Schedule:
| Weeks | Dose | Frequency |
|---|---|---|
| 1-4 | 0.5-1mg | Weekly |
| 5-8 | 2mg | Weekly |
| 9-12 | 4mg | Weekly |
| 13-16 | 6mg | Weekly |
| 17-20 | 8mg | Weekly |
| 21-24 | 10mg | Weekly |
| 25+ | 12mg | Weekly (maximum studied) |
Important Considerations:
- Titration is essential - Do not skip steps
- Slower titration may be needed based on tolerability
- Optimal dose varies - Some may plateau at 8mg or 10mg
- Weekly injection similar to semaglutide and tirzepatide
Side Effect Profile
GI Side Effects (Most Common):
Similar to other GLP-1 agonists but with nuances:
Nausea: 20-30% of participants
- Usually mild to moderate
- Improves with continued use
- Dose-dependent
Diarrhea: 15-25%
- More common than constipation (differs from semaglutide)
- Related to glucagon component
Vomiting: 10-15%
- Usually early in treatment
- Improves with titration
Decreased Appetite:
- Expected therapeutic effect
- Still need adequate protein intake
Glucagon-Related Effects:
The glucagon component may cause:
- Increased heart rate (mild)
- Potential for blood sugar elevation in fasted state
- Increased energy/alertness
Reported Side Effects (Phase 2):
- GI effects: 35-50% (decreased with slower titration)
- Injection site reactions: 5-10%
- Fatigue: 5-8%
- Headache: 5-8%
Serious Adverse Events:
Similar warnings to other GLP-1 agonists:
- Theoretical thyroid tumor risk (boxed warning expected)
- Pancreatitis risk (low)
- Gallbladder issues
Retatrutide vs Tirzepatide vs Semaglutide
| Factor | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Mechanism | Triple (GIP+GLP-1+Glucagon) | Dual (GIP+GLP-1) | Single (GLP-1) |
| Avg Weight Loss | 24% (12mg) | 21% (15mg) | 17% (2.4mg) |
| Max Dose Studied | 12mg weekly | 15mg weekly | 2.4mg weekly |
| Energy Expenditure | Increased | Minimal change | Minimal change |
| FDA Status (2026) | Phase 3/Pending | Approved | Approved |
| Diarrhea vs Constipation | More diarrhea | Mixed | More constipation |
Key Advantages of Retatrutide:
- Greater weight loss potential (24% vs 21% vs 17%)
- Increased energy expenditure (glucagon effect)
- Better muscle preservation (theoretical, from glucagon)
- Potential metabolic benefits beyond weight loss
Who Might Benefit Most
Ideal Candidates:
- Those seeking maximum weight loss
- Plateau on semaglutide or tirzepatide
- Metabolic syndrome with fatty liver
- Need for preserved muscle mass during weight loss
Potential Contraindications (Expected):
- Medullary thyroid carcinoma history
- MEN2 syndrome
- History of pancreatitis
- Pregnancy/breastfeeding
- Severe GI disorders
Practical Considerations
Current Availability (2026):
- Clinical trials (check clinicaltrials.gov)
- Research chemical suppliers (unverified quality)
- FDA approval pending
When FDA Approved (Expected):
- Prescription-only medication
- Likely brand name pricing similar to Mounjaro
- Insurance coverage uncertain initially
Preparing for Retatrutide:
If considering when available:
- Establish baseline labs
- Build exercise habits now
- Optimize protein intake
- Work with healthcare provider
- Understand realistic expectations
Future Outlook
What to Watch:
- Phase 3 TRIUMPH trial results
- FDA approval timeline
- Combination studies
- Long-term safety data
- Real-world effectiveness data
The Evolution of GLP-1 Therapy:
- Gen 1: GLP-1 alone (semaglutide, liraglutide)
- Gen 2: GLP-1 + GIP (tirzepatide)
- Gen 3: GLP-1 + GIP + Glucagon (retatrutide)
- Future: Additional combinations in development
Related Content
Disclaimer: This content is for educational purposes only and is not medical advice. Retatrutide is an investigational compound not yet FDA-approved. Information is based on clinical trial data. Consult a healthcare provider before starting any treatment.
Source: https://peptides.nyc/learn/retatrutide-protocol
This content is produced by the Peptides.NYC editorial team from published research. It has not been reviewed by a licensed clinician and is educational only — always consult your healthcare provider before starting, stopping, or adjusting any peptide protocol.
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
This article cites peer-reviewed research and medical literature. Click any reference to view the original source.
- 1
Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, et al. (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial N Engl J Med.
- 2
Jastreboff AM, Kaplan LM, Hartman ML (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply N Engl J Med.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.